1、TIA,Living with OCDAND HELPING RECRUIT IN BIOHAVEN CLINICAL TRIALS42nd Annual J.P.Morgan Healthcare ConferenceVlad Coric,M.D.Chairman and Chief Executive OfficerJanuary 8,2024 2024 Biohaven,Ltd.All rights reserved.Forward-Looking StatementThis presentation includes forward-looking statements within

2、the meaning of the Private Securities Litigation Reform Act of 1995,including statements about Biohaven Ltd.(the“Company”)and our planned and ongoing clinical trials,the timing of and the availability of data from those trials,the timing and our decisions to proceed with our planned regulatory filin

3、gs,the timing of and our ability to obtain regulatory approvals for our product candidates,the clinical potential utility of our product candidates,alone and as compared to other existing potential treatment options,and the potential advancement of our early phase programs.The use of certain words,i

4、ncluding“continue”,“plan”,“will”,“believe”,“may”,“expect”,“anticipate”and similar expressions,is intended to identify forward-looking statements.Investors are cautioned that any forward-looking statements,includingstatements regarding the future development,timing and potential marketing approval an

5、d commercialization of our development candidates,are not guarantees of future performance or results and involve substantial risks and uncertainties.Actual results,developments and events may differ materially from those in the forward-looking statements as a result of various factors including:the

6、 expected timing,commencement and outcomes of Biohavens planned and ongoing clinical trials;the timing of planned interactions and filings with the FDA;the timing and outcome of expected regulatory filings;complying with applicable U.S.regulatory requirements;the potential commercialization of Bioha

7、vens product candidates;the potential for Biohavens product candidates to be first in class and best in class therapies;the anticipated consummation of the Trop2 transaction,andthe effectiveness and safety of Biohavens product candidates.You should,therefore,not rely on these forward-looking stateme

8、nts as representing our views as of any date subsequent to the date of this presentation.Additional important factors to be considered in connection with forward-looking statements are described in the Companys filings with the Securities and Exchange Commission,including within the sections titled“

9、Risk Factors”and“Managements Discussion and Analysis of Financial Condition and Results of Operations”.The forward-looking statements are made as of the date of this presentation,and Biohaven does not undertake any obligation to update any forward-looking statements,whether as a result of new inform

10、ation,future events or otherwise,except as required by law.This presentation also contains market data and other information based on industry publications,reports by market research firms or published independent sources.Some market data and information is also based on the Companys good faith esti

11、mates,which are derived from managements knowledge of its industry and such independent sources referred to above.January 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference2GROUNDBREAKING LEGACY OF SUCCESS IN MIGRAINE BiohavenBiohaven has reemerged forhas reemerged forcountless patients and

12、 is growing one of thecountless patients and is growing one of themost innovative portfolios in life sciences.most innovative portfolios in life sciences.NEUROSCIENCE|IMMUNOLOGY|ONCOLOGY Top Areas of InnovationBIOHAVEN PORTFOLIOPositioned for Future Value Creation for Patients and Investors IgG Degr

13、aderTYK2/JAK1Kv7 Activator TRPM3 Antagonist TroriluzoleTaldefgrobep AlfaTrop2CD301-AR Degrader IgA Degrader RARE DISEASERENALCARDIOVASCULARONCOLOGYOBESITYNEUROLOGYIMMUNOLOGY&INFLAMMATION1.Adapted from BioCentury survey:https:/ 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference4PRECLINICALPH

14、ASE 1PHASE 2PHASE 3MARKETGLUTAMATETroriluzoleBHV-4157Obsessive-Compulsive DisorderMYOSTATINTaldefgrobep AlfaBHV-2000Spinal Muscular AtrophyObesityION CHANNELKv7 ActivatorBHV-7000Focal EpilepsyGeneralized EpilepsyBipolar Disorder Major Depressive Disorder TRPM3 AntagonistBHV-2100Migraine Neuropathic

15、PainINFLAMMATION&IMMUNOLOGYTYK2/JAK1 Inhibitor(brain penetrant)BHV-8000Prevention of Amyloid Therapy Induced ARIAEarly Alzheimers Disease Early Parkinsons DiseaseMultiple SclerosisIgG DegraderBHV-1300Rheumatoid ArthritisBHV-1310Myasthenia GravisIgA DegraderBHV-1400IgA Nephropathy1-AR DegraderBHV-160

16、0Dilated CardiomyopathyONCOLOGYCD38BHV-1100Multiple MyelomaTrop2BHV-1510CarcinomaCD30(next-gen brentuximab vedotin)BHV-1500Hodgkins LymphomaARIA,Amyloid-related imaging abnormalities Ion ChannelsBHV-7000 Kv7.2/7.3 ActivatorPotassium(K+)Ion ChannelBHV-7000SELECTIVE Kv7 ACTIVATORKv7 is Breakthrough Ta

17、rget in Neurology and Neuropsychiatry Selective Kv7 activation avoids unwanted CNS side effects Clinically validated in epilepsy and major depressive disorderBHV-7000 is Potentially Best-in-class Selective Kv7 Activator with Blockbuster Potential Rationally designed to eliminate GABAA receptor activ

18、ation No dose-limiting CNS side effects in Phase 1 studies CNS target engagement confirmed in a dose proportional manner in Phase 1 EEG studyBHV-7000 Has Compelling Preclinical Efficacy Profile Highly effective in epilepsy model Ketamine-like efficacy in neuropsychiatry model Wide therapeutic index

19、to explore full dose range7Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Phase 2/3 Epilepsy Update:110 global clinical sites selected,FPFV 1Q24Phase 2 MDD and Bipolar Studies expected to initiate FPFV 1Q24BREAKINGNEWSBHV-7000:Epilepsy UpdateION CHANNELSDialing Out GABAA Receptor

20、 Activation Now Clinically Proven to Reduce CNS Side EffectsPooled CNS AEsBHV-7000MAD PooledN=29XEN1101 MAD PooledN=18Somnolence0%39%Headache21%39%Balance disorder/dizziness10%34%Memory impairment0%28%Sensory disturbance0%11%Speech disorder0%33%BHV-70009Biohaven|42nd Annual J.P.Morgan Healthcare Con

21、ferenceJanuary 8,2024PHASE 1Not associated with CNS AEs typical of other ASMs in healthy volunteersEEGMinimal impact on spectral power in slower frequencies(i.e.,delta)consistent with lack of somnolence in Phase 1PRECLINICALNo effects on motor performance on rotarodVehicle0.31 3 10 30 050

22、0BHV-7000(mg/kg)Time to fall(sec):Rotarod250200150100500Time to fall(sec)Vehicle0.3131030BHV-7000XEN1101INCREASED DELTABaseline50mg1086420Power(mV/m2)2)/Hz)051015202530Frequency(Hz)BHV-7000CNS Target Engagement Confirmed at Concentrations Well-Tolerated and Exceeding Predicted Therapeutic Target Lev

23、els10Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Demonstrated CNS target engagement in EEG spectral power across all frequency bands,in a dose proportional mannerFormulated an extended release once-a-day tablet predicted to achieve target concentrationsTIMEPOINTSGAMMABETAALPHA

24、THETADELTAPREDOSE123(Tmax)45MES EC50MES EC20Mean predicted BHV-7000 plasma concentrations(ng/mL)04812162024Time post dose(h)25 mg QD50 mg QD75 mg QDEstablished ASM translational target*EC50 based on preclinical maximal electroshock seizure(MES)models Dose/time dependent EEG changes confirm target en

25、gagementKEYPOINTEpilepsy Phase 3 Studies in Focal and Idiopathic Generalized EpilepsyJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference11BHV-7000Focal DesignGeneralized DesignFocal Epilepsy Study 110 global clinical sites selected,FPFV 1Q24KEYPOINTDESIGNRandomized,double-blind,place

26、bo-controlled trialPOPULATIONSubjects 1875 years old with intractable focal epilepsySAMPLE SIZE 390 subjects(randomized 1:1:1)TREATMENTBHV-7000(75/50 mg)and(50/25 mg)vs.placeboTREATMENT DURATION 12-or 8-week treatment phaseENDPOINTSChange in seizure frequency,50%seizure reduction,seizure freedom,saf

27、etyDESIGN Randomized,double-blind,placebo-controlled trialPOPULATIONSubjects 1875 years old with idiopathic generalized epilepsy with intractable generalized tonic-clonic seizuresSAMPLE SIZE 242 subjects(randomized 1:1:),study ends with the 127th seizure eventTREATMENT BHV-7000 75 mg vs.placeboTREAT

28、MENT DURATION Up to 24-week double-blind phase,subject will transition to open label extensionENDPOINTS Time to event(2nd day with generalize tonic-clonic seizure)BHV-7000:Neuropsychiatry UpdatesION CHANNELSKv7 Activation Validated in the Clinic for Major Depressive Disorder13012345-20-15-10-50Chang

29、e in MADRS scoreWeeks 7.9-point benefit vs.placebo on MADRS(p0.001)6.9-point benefit vs.placebo on SHAPS(p0.001)Dose-limiting side effects in 20%of study subjectsEzogabine Demonstrated Robust Clinical Benefit(n=45)1 Benefit on MADRS(p=0.135)vs.placebo in 20 mg group Benefit on MADRS at week 1(p350 s

30、ubjects with favorable safety and tolerability observed in children,adolescents,and adults Reductions in fat mass while increasing lean mass in healthy adults Maintains muscle gains after cessation of administrationWeekly SC administration with the potential for extended dosing intervalsPhase 3 in S

31、MAGlobal Phase 3 study in broad-population of SMA patients now fully enrolledWeekly SC taldefgrobep alfa on top of stand of care continues to be well toleratedOrphan designation granted in the US and EU,along with Fast Track designation by FDA20Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJa

32、nuary 8,2024Obesity Phase 2 to initiate in 2Q 2024Topline Phase 3 Results in SMA in 2H 2024BREAKINGNEWSMuscle Is an Important Endocrine Organ in Metabolic ActivityJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference21TaldefgrobepMYOKINESplay an important role in regulating fat metabol

33、ism,inflammation,appetite,glucose control,bone density,and basal metabolic rateLEAN MUSCLE MASS-DERIVED MYOKINES signal to numerous organ systems impacting overall health and wellness,beyond physical performance1LOW MUSCLE MASS is associated with age-related cognitive decline2 and increase in all-ca

34、use mortality3Bone formationImproves aging skinAdipose tissueHippocampal neurogenesisAppetiteBrain-derived neurotrophic factor(BDNF)Lipolysis BrowningGLP-1Gastrointestinal tractPancreasHepatic glucose production during exerciseLiverInsulinAMPKGlucose uptakeFat oxidationHypertrophyBrainMyokinesIllust

35、ration adapted from Severinsen et al.Endocr Rev.2020 Aug 1;41(4):594609.2.Daghlas et al.BMJ Med.2023;2(1):e000354.3 Lee et al.Exp Biol Med.2018;243:1275-85.Taldefgrobep alfa increases lean muscle mass leading to improvements in metabolism and weight managementKEYPOINTIncreased lean massReduction in

36、total body fat massImproved insulin sensitivityReduction in visceral fatReduction in intramuscular fatReduction in intrahepatic fatIncreased basal metabolic rateImproved bone mineral densityInhibiting Myostatin Increases Muscle Mass and Metabolic HealthTaldefgrobepMyostatin as a Pharmacologic Target

37、22Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Taldefgrobep Alfa:A Differentiated Therapeutic Approach Balances Efficacy and SafetyJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference23TaldefgrobepALK4ALK5ActRIIBSKELETAL MYOCYTESMAD2/3/4 SIGNALINGSignal transduct

38、ion of muscle growth inhibition through ALK4/5 and ActRIIBTARGETS pro-and latent myostatinALK4ALK5ActRIIBALK4ALK5ActRIIBMMGAMAMApitegromabScholar RockTaldefgrobep alfaBiohavenBimagrumabVersanis-LillyBLOCKS active myostatin and INHIBITS ActRIIB signalingBLOCKS ActRIIB signalingwith very high affinity

39、MGAMyostatin(GDF-8)Growth Differentiation Factor 11(GDF-11)ActivinCYTOKINE INHIBITORS OF MUSCLE GROWTH THROUGH ActRIIBSC Taldefgrobep Effectively Suppresses Free Myostatin in Healthy AdultsJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference24Free Myostatin Levels Myostatin Complex Le

40、velsTaldefgrobepLAST DOSELAST DOSEComplex sustains activityRobust lowering of free myostatin after administration of taldefgrobep alfa 45 mg Q1WTaldefgrobep-myostatin complex continues to exert activity for weeks after dosing stopsContinued improvement in muscle mass after cessation of dosingKEYPOIN

41、TSTaldefgrobep alfa activity sustained by circulating taldefgrobep-myostatin complex Biohaven Phase 1 data on file Biohaven Phase 1 data on file TaldefgrobepTaldefgrobep Alfa:Demonstrates Fat Reduction While Improving Lean Mass in Healthy AdultsTaldefgrobep Alfa Demonstrates Continued Improvement in

42、 Lean Mass in Healthy Adults at 30 Days Post-dosingTaldefgrobep Alfa Continued to Decrease Total Fat Mass Beyond the Dosing Period-10-8-6-4-202468Day 29Day 57Fat Body Mass(%change)Placebo45 mg Q1W45 Q1W543210-1-20152957Mean%Change from BaselineLean Body MassStudy DayPlacebo45 Q1WLAST DOSEContinued i

43、mprovement in lean massPBOLAST DOSEDose Administered25Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Biohaven Phase 1 data on file Biohaven Phase 1 data on file Taldefgrobep Alfa:Phase 2 Study to Evaluate Taldefgrobep+/-Semaglutide in the Treatment of Overweight and Obesity Innov

44、ative study design allows for early insight into a number of key clinical questions Impact of Taldefgrobep monotherapy on changes in body composition,total body weight,and metabolic parameters Ability of Taldefgrobep to augment fat mass loss when used as adjunct to anti-obesity standard of care(GLP-

45、1 agonist)Potential for Taldefgrobep to prevent against GLP-1-induced lean muscle loss Influence of Taldefgrobep on weight regain following discontinuation of GLP-1 agonistJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference26Post-Dose Follow-upTaldefgrobep(n=30)Taldefgrobep+Semagluti

46、de(n=30)Semaglutide(n=30)Screening4 WeeksPRIMARY DATA READOUTWeek 18Taldefgrobep+Semaglutide(n=30)Semaglutide(n=30)Semaglutide(n=30)Week 36TaldefgrobepPhase 2 Proof of Concept Study Initiation in 1H24KEYUPDATE3M+OCD Patients in US With High Unmet Medical Need4060%do not respond to first line treatme

47、nt 1040%are treatment refractory potentially requiring ablative neurosurgery or deep brain stimulationPhase 2 Troriluzole Trial in OCD Demonstrated Efficacy SignalConsistent numerical benefits vs.placebo on Y-BOCS(primary endpoint)at all timepoints(weeks 4 to 12);p 90%deep reduction in target Allows

48、 for selective targeting of proteins to avoid broad immunosuppression Ability to adjunctively dose Fc biologics K E Y I N F L E C T I O N P O I N T S202320242025IgG RA-Autoimmune BHV-1300IgG BHV-1310IgA IgA Nephropathy BHV-14001-AR Cardiomyopathy BHV-1600Novel autoantibody targetsMoDE Degraders:Mult

49、iple Asset Opportunities and Potential TimelinesRealization of value inflection points will be project specific and aligned with cohesive portfolio strategy,Late timelines are considered approximateAutoAb,autoantibody;Ig,immunoglobulin;IND,Investigational New Drug;MoDE,molecular degrader of extracel

50、lular proteins;RA,rheumatoid arthritisPhase 1(1Q)IND FilingIND FilingIND Filing1 0 I N D s E X P E C T E D o v e r n e x t 3 y e a r s IgG,IgA and 1-AR antibodies are the first targets for Biohavens powerful degradation platform32Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024BHV

51、-1300DEGRADERSBHV-1300:Shows Potential for Superiority Over CompetitionBHV-1300 demonstrated faster depletion of IgG in non-human primates0505%IgG,baselineDays after start of infusion10 mg/kg75 mg/kg250 mg/kgVehicleBHV-1300 NHP Pharmacodynamics23 days to reach 80%depletion Efgartigimod NH

52、P Pharmacodynamics57 days to reach 50%depletion0550Days after start of infusion%IgG,baselineVehicle0.2 mg/kg2 mg/kg20 mg/kg70 mg/kg200 mg/kgImmunovant NHP Pharmacodynamics0 7 14 21 28 35 42 56 Days%change/T00102550100Batoclimab 50 mg/kg(n=3)IMVT-1402 50 mg/kg(n=7)IMVT-1402 5 mg/kg(n=7)Pla

53、cebo(n=7)21 days to reach 75%depletionBHV-1300Dose AdministeredUlrichts P et al,J Clin Invest.2018 Oct 1;128(10):4372-4386.doi:10.1172/JCI97911.Epub 2018 Jul 24.PMID:30040076;PMCID:PMC6159959.Excerpted from Immunovant Corporate Presentation,August 2023.34Biohaven|42nd Annual J.P.Morgan Healthcare Co

54、nferenceJanuary 8,2024Unique Properties of BHV-1300 and BHV-1310 Matched to Indications BHV-130035Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024BHV-1310 Preclinical Pharmacodynamics(single dose)BHV-1300 Preclinical Pharmacodynamics(multiple dose)Dose Administered60%DEPLETION90%D

55、EPLETIONDose Administered60%DEPLETION90%DEPLETIONOptimization of degrader technology(BHV-1310)allows for deeper reductions in IgG after single doseKEYPOINTACUTE indications e.g.,myasthenia gravisCHRONIC indications e.g.,rheumatoid arthritisBHV-1300 pharmacodynamics in NHP and BHV-1310 pharmacodynami

56、cs in rabbitBiohaven Pan-IgG Degraders Allow for Co-Administration with mAbsJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference36BHV-1300*Adapted from BLA 761154,IND 116471,Study no.r-fkb327-01Humira 3 mg/kg SC,After a 30 mg/kg SC Dose of BHV-1300 to NHPTime(days)Mean concentration(g

57、/mL)Humira dosed 2h post BHV-1300Humira dosed 12h post BHV-1300Humira*Frequently Administered Fc-Containing BiologicsHumiraEnbrelRemicadeCosentyxRituxanActemraTremfyaRepathaProliaFirst NHP data to show that BHV-1300 does not alter PK of Humira when dosed 12 hours earlierAllows for same-day dosing wi

58、th biologics FcRns reduce effectiveness of Fc-containing biologics and should not be used chronically togetherKEYPOINTSBHV-1600,Next-Generation Selective DegraderTargeting 1-AR AutoantibodiesDEGRADERSSelective Targeting of 1-AR Autoantibodies for Dilated CardiomyopathyBHV-1600Cardiac beta-adrenergic

59、 receptors(1-AR)Inducibly increases heart rate,contractility and cardiac outputAgonistic autoantibodies to 1-AR increase basal heart rateSustained 1-AR agonism dilated cardiomyopathy heart failureAdenylyl cyclasePKAGSPCaspaseL-typeCa2+ChannelATP cAMPCa2+ApoptosisNORMAL HEARTDILATED CARDIOMYOPATHY1-A

60、R autoantibodies 1-AR autoantibodies CURRENT TREATMENT FOR 1-AR AUTOANTIBODY-DRIVEN CARDIAC DISEASE:BETA BLOCKERS:Ineffective treatment limited to supportive treatment,diuresis,etc.REMOVAL OF ANTIBODIES:Plasmapheresis1,2 demonstrates POC but requires hospitalization1.Eur J Heart Fail.2013;15(7):7247

61、29.2.Nat.Rev.Nephrol.2014;10(3):125-125.Illustration adapted from European Journal of Heart Failure(2013)15,724729.Heart image adapted from https:/ targeted hepatic degradation of autoantibodies38Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024IND Filing and FIH Phase 1 Study 2H 2

62、024KEYUPDATETernary Complex and EndocytosisMarked Degradation of Anti-1AR Antibody in MiceBHV-1600:In Vitro and In Vivo Properties Ideal for Degrading-1AR AbsBHV-1600High Affinity to the TargetHigh affinity for monoclonal mouse anti-b1-AR antibody and ASGPR protein construct by SPR Rapid ASGPR-media

63、ted hepatic clearance in mouse and rat Stoichiometric degradation of exogenously administered anti-b-1AR Ab in mice compared to controlsFormation of ternary complex confirmed in TR-FRET assayCellular internalization of anti-b-1AR Ab demonstrated in HEK293(hASGPR)cells066080100Time(Hrs)%an

64、ti-1ARPBSPeptide AloneBHV-1600January 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference39KD B1AR=18 nMBHV-1600First-in-Class Oral,Selective,Brain-Penetrant TYK2/JAK1 Inhibitor Uniquely potent,TYK2/JAK1 selective,brain-penetrant inhibitor Selectivity profile should avoid class risks associa

65、ted with JAK2/3 inhibitionBreaks the Cycle of NeuroinflammationReduces inflammatory impacts of microglia,astrocytes,and infiltrating T-lymphocytesPotential to Treat Multiple Neuroinflammatory DisordersEvidence supports efficacy in prevention of amyloid therapy induced ARIA,Alzheimers disease,Parkins

66、ons disease,Multiple Sclerosis and other disordersEncouraging Preliminary Results from Ongoing Phase 1 Trial Projected therapeutic concentrations achieved Well tolerated with only mild adverse events to date(loose bowel movements,headache,and constipation)Upcoming MilestonesAnticipate initiating mul

67、tiple clinical trials in 2024BHV-8000TYK2/JAK1 INHIBITOR(brain-penetrant)ARIA,Amyloid-related imaging abnormalities SAD study:SAD cohorts completed dosing(10,20 and 30 mg)MAD study:Completed 10 mg dose cohort and began 20 mg dosePROGRAMUPDATE40Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJan

68、uary 8,2024BHV-8000:TYK2/JAK1 in Neuroinflammatory DisordersCytokineReceptorJAKFAMILYMicrogliaIFN-,IFN-,IFN-AstrocytesIFN-,IFN-and IFN-Lymphocytes and Other LeukocytesIL-23,IL-17 downstream of IL-23CELLULAR DRIVERS IN NEUROINFLAMMATIONInflammation plays a key role in the pathogenesis of neurodegener

69、ative diseasesNonclinical,clinical,genetic and epidemiological data show that interrupting chronic inflammation may slow disease progressionARIAAlzheimersParkinsonsMultiple Sclerosis Other Neuroinflammatory&Neurodegenerative DisordersJAK2JAK1TYK2STAT SIGNALINGBHV-8000JAK3BHV-8000A dual,brain-penetra

70、nt inhibitor of TYK2 and JAK1 that can effectively block Th17 cell generation,Type I IFN signaling and inflammation 41Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024Biohavens Real-World Analytics of Large Healthcare Database:Parkinsons Disease Risk Reduction with IL-17/TNF Target

71、ing Therapies Biohaven conducted analysis using Komodo Health database(over 320 million patients since 2012)examining treatment with Anti-TNF or Anti-IL17 and incidence of PD Millions of patients over 8+years of dosing captured key epidemiologic confirmation of the neuroinflammatory hypothesis Resul

72、t provides MOA rationale for the effectiveness of a TYK/JAK inhibitor in PDTreatmentPD EventsPerson-yearsRate(per 100 person-years)Adjusted IRR(95%CI)P-valueAnti-TNF or Anti-IL-17 exposure2,957393,1140.660.77(0.74 0.80)0.0001No Treatment50,5625,328,3070.95Anti-TNF exposure2,471371,8670.660.64(0.52 0

73、.80)0.0001No Treatment50,5625,328,3070.95Anti-IL-17 exposure8115,5980.520.77(0.78 0.81)$5.25B,subject to annual cap($400M/year)31.As of October 5,2023,including cash from the completed Oct 2023 common offering,marketable securities,and investments.2.Excludes outstanding options.3.Cap reach if aggreg

74、ate annual U.S.net sales of rimegepant and zavegepant amount to$8.15B.Royalty payments would be in respect of years ended on or before 12/31/40.53Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,2024BIOCENTURY SURVEY11.Adapted from BioCentury survey:https:/ numbers are US prevalence fr

75、om Biohaven market research;3.With amyloid therapy;4.Disease modifyingPATIENTS 2INDICATIONIgA Degrader 3.5M IgA NEPHROPATHYRARE DISEASERENALCARDIOVASCULARONCOLOGYOBESITYNEUROLOGYIMMUNOLOGY&INFLAMMATION54Biohaven|42nd Annual J.P.Morgan Healthcare ConferenceJanuary 8,20241AR Degrader 388K DILATED CARD

76、IOMYOPATHYTrop2660K EPITHELIAL TUMORSCD30173K HODGKINS LYMPHOMATaldefgrobep Alfa10K SPINAL MUSCULAR ATROPHY10M OBESITYTroriluzole2.6M OBSESSIVE-COMPULSIVE DISORDERTRPM3 Antagonist 40M MIGRAINE 36M PAINKv7 Activator 2M FOCAL EPILEPSY7M BIPOLAR DISORDER1.2M GENERALIZED EPILEPSY21M MAJOR DEPRESSIVE DIS

77、ORDERTYK2/JAK10.5M EARLY PARKINSONS DISEASE3.5M ARIA PREVENTION2950K MULTIPLE SCLEROSIS3.5M EARLY ALZHEIMERS DISEASE380130K RHEUMATOID ARTHRITIS100K MYASTHENIA GRAVISIgG DegraderBiohavens pipeline working to help millions of patients 1Q 20242Q 20242H 2024Troriluzole|BHV-4157Obsessive-Compulsive Diso

78、rderTaldefgrobep Alfa|BHV-2000Spinal Muscular AtrophyObesityKv7 Activator|BHV-7000Focal EpilepsyGeneralized EpilepsyBipolar DisorderMajor Depressive Disorder TRPM3 Antagonist|BHV-2100MigraineNeuropathic PainTYK2/JAK1|BHV-8000(brain-penetrant)Prevention of Amyloid Therapy Induced ARIAEarly Alzheimers

79、 Disease Early Parkinsons Disease Multiple SclerosisIgG Degrader|BHV-1300Rheumatoid ArthritisIgG Degrader|BHV-1310Myasthenia Gravis IgA Degrader|BHV-1400IgA Nephropathy1-AR Degrader|BHV-1600Dilated CardiomyopathyCD30|BHV-1500Hodgkins LymphomaTrop2|BHV-1510Carcinoma2024 Milestones:Potential for Multi

80、ple Value Inflection PointsInitiate Phase 2/3Initiate Phase 2Initiate Phase 2/3Initiate Phase 2Initiate Phase 2Initiate Phase 2/3Initiate Phase 2/3Phase 1 IgG Lowering DataInitiate Phase 1Initiate Phase 1File INDPhase 3 IA ToplineInitiate Phase 2Phase 3 ToplineInitiate Phase 2/3Initiate Phase 1Initiate POCInitiate Phase 2aJanuary 8,2024Biohaven|42nd Annual J.P.Morgan Healthcare Conference55Initiate Phase 1Database Lock Our Commitment:Building Value for Patients and Shareholders